Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

about

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

Item

http://www.wikidata.org/entity/Q47835081

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

@en

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

@nl

type

Item

label

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

@en

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

@nl

prefLabel

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

@en

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

@nl

P1476

Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.

@en

P2093

Chae-Yong Kim

http://www.w3.org/2001/XMLSchema#string

Jung Ho Han

http://www.w3.org/2001/XMLSchema#string

Kyoungyul Lee

http://www.w3.org/2001/XMLSchema#string

Kyu Sang Lee

http://www.w3.org/2001/XMLSchema#string

Seyoung Moon

http://www.w3.org/2001/XMLSchema#string

Sumi Yun

http://www.w3.org/2001/XMLSchema#string

Yujun Park

http://www.w3.org/2001/XMLSchema#string

P2860

IDH1 and IDH2 mutations in gliomas

PD-L1 expression in human cancers and its association with clinical outcomes

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Gliomas and the vascular fragility of the blood brain barrier

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Pembrolizumab for the treatment of non-small-cell lung cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

P2888

s11060-017-2675-6

P31

scholarly article

P356

10.1007/S11060-017-2675-6

http://www.w3.org/2001/XMLSchema#string

P50

Hye Seung Lee

Gheeyoung Choe

P577

2017-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29147863

http://www.w3.org/2001/XMLSchema#string